Form SCHEDULE 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]
SEC Accession No. 0001104659-25-059524
Filing Date
2025-06-13
Accepted
2025-06-13 19:43:14
Documents
1

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13D/A  
1 primary_doc.xml SCHEDULE 13D/A 33876
  Complete submission text file 0001104659-25-059524.txt   35647
Mailing Address 1920 MCKINNEY AVENUE 7TH FLOOR DALLAS TX 75201
Business Address 1920 MCKINNEY AVENUE 7TH FLOOR DALLAS TX 75201 972-277-1136
Lantern Pharma Inc. (Subject) CIK: 0001763950 (see all company filings)

EIN.: 463973463 | State of Incorp.: TX | Fiscal Year End: 1231
Type: SCHEDULE 13D/A | Act: 34 | File No.: 005-91536 | Film No.: 251048142
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address 1751 RIVER RUN, SUITE 400 FORT WORTH TX 76107
Business Address 1751 RIVER RUN, SUITE 400 FORT WORTH TX 76107 817-381-5370
Bios Equity Partners, LP (Filed by) CIK: 0001813314 (see all company filings)

EIN.: 822422973 | State of Incorp.: TX | Fiscal Year End: 1231
Type: SCHEDULE 13D/A